摘要
肿瘤的形成、进展及其转移与多种基因突变和细胞信号传导通路密切相关,包括异常的生长因子激活,细胞分裂信号途径持续活化(如Raf/MEK/ERK、PI3K/AKT和Wnt/β2catenin通路),抗细胞凋亡信号途径失调(如p53和PTEN基因)和新生血管异常增生等。近年来,伴随着分子生物学技术和理论的发展,分子靶向抗肿瘤药物在临床实践中已取得了显著的疗效,且多靶点分子靶向药物已成为抗肿瘤药物研究的重点。
Tumor formation, progression and metastasis are most associated with a variety of gene mutation and cell signaling path- ways, including the activation of abnormal growth factor, continuing activating cell division signaling pathways（ Raf/MEK/ERK, PI3K/ AKT and Wnt/152catenin pathways）, dysregulation of apoptosis signal pathway, blood vessels dysplasia and so on. With the development of molecular biology technology and theory make a spurt of progress, molecular targeted cancer drugs has made significant effect on clini- cal practice in recent years. Molecularly targeted drugs has became the focus of research of anti-tumor drugs.
出处
《中国药物评价》
2013年第5期271-277,共7页
Chinese Journal of Drug Evaluation
基金
浙江省科技厅国际合作重大专项:"国家一类肝癌治疗药BZG-4000的作用机理和药效学研究"(2009C14030)
国家十二五"重大新药创制"科技部重大专项:"抗感染创新药物临床评价研究技术平台建设"(2011ZX09302-003-03)
关键词
分子靶向药物
抗肿瘤药
肿瘤
Molecular targeted drugs
Anti-tumor drugs
Tumor
